

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
CREDIT SUISSE AG	01/31/2011
RECEIVING PARTY DATA	
Name:	ALPHARMA PHARMACEUTICALS LLC
Street Address:	501 FIFTH STREET
City:	BRISTOL
State/Country:	TENNESSEE
Postal Code:	37620
PROPERTY NUMBERS Total: 17	
Property Type	Number
Application Number:	10667570
Application Number:	10667676
Application Number:	11159894
Application Number:	11820499
Application Number:	11913699
Application Number:	11973802
Application Number:	12204280
Application Number:	12336267
Application Number:	12336418
Application Number:	12337052
Application Number:	12418806
Application Number:	12710016
Application Number:	12766472
Application Number:	12766488
Application Number:	12766509

501424736

PATENT  
REEL: 025735 FRAME: 0424

CH \$680.00 10667570

Patent Number:	7682633
----------------	---------

Patent Number:	7682634
----------------	---------

**CORRESPONDENCE DATA**

Fax Number: (202)778-6493

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 202-662-6493

Email: kashton@cov.com

Correspondent Name: Covington &amp; Burling LLP

Address Line 1: 1201 Pennsylvania Avenue, N.W.

Address Line 2: Attn: Patent Docketing

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004-2401

ATTORNEY DOCKET NUMBER:	029459.00030
-------------------------	--------------

NAME OF SUBMITTER:	Andrea Reister
--------------------	----------------

**Total Attachments: 4**

source=Alpharma Pharmaceuticals LLC Patent Release#page1.tif

source=Alpharma Pharmaceuticals LLC Patent Release#page2.tif

source=Alpharma Pharmaceuticals LLC Patent Release#page3.tif

source=Alpharma Pharmaceuticals LLC Patent Release#page4.tif

## **Release of Security Interest in Patents**

**January 31, 2011**

**WHEREAS**, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

**WHEREAS**, pursuant to the GCA, Credit Suisse and Alpharma Pharmaceuticals LLC, a Delaware limited liability company (the “**Assignee**”), entered into that certain Patent Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 14, 2010 on Reel No. 024380, Frame No. 0864 (the “**Patent Security Agreement**”);

**WHEREAS**, under the Patent Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Patent Collateral (as defined in the Patent Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Patent Collateral**”);

**WHEREAS**, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

**WHEREAS**, Credit Suisse desires to release the security interest granted by the Assignee under the Patent Security Agreement in the Released Patent Collateral.


**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Patent Security Agreement in the Released Patent Collateral and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee, without any representation or warranty by, or recourse to, Credit Suisse, all right, title and interest of Credit Suisse in, to and under such Released Patent Collateral granted under the Patent Security Agreement. This Release of Security Interest in Patents shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Patents against the Released Patent Collateral.

*[signature page to follow]*

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Patents to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN  
ISLANDS BRANCH

By:   
Name: **DOREEN BARR**  
Title: **DIRECTOR**

By:   
Name: **VIPUL DHADDA**  
Title: **ASSOCIATE**

*[signature page – Alharma Pharmaceuticals LLC patent release]*

**Schedule 1**

**ALPHARMA PHARMACEUTICALS LLC**

**PATENTS AND PATENT APPLICATIONS**

<b>Internal Title</b>	<b>Filing #</b>	<b>Grant #</b>	<b>Type<sup>1</sup></b>	<b>Expiration</b>
Sustained-Release Opioid Formulations And Methods Of Use	10/667,570	N/A	NP	09/22/2023
Sequestering Subunit And Related Compositions And Methods	10/667,676	N/A	NP	09/22/2023
Morphine Sulphate Formulations	11/159,894	N/A	NP	06/23/2005
Pharmaceutical Compositions ("Optimization")	11/820,499	N/A	NP	06/19/2026
Morphine Sulfate Formulations	11/913,699	N/A	NP	05/12/2026
Pharmaceutical Compositions ("Phase II")	11/973,802	N/A	NP	10/10/2026
Pharmaceutical Compositions ("Al-06-04-205 Crushed")	12/204,280	N/A	NP	09/04/2027
Pharmaceutical Composition ("302 Clinical Trial")	12/336,267		NP	12/16/2008
Pharmaceutical Composition ("301 Clinical Trial")	12/336,418		NP	12/16/2028
Pharmaceutical Composition ("Oxycodone")	12/337,052		NP	12/17/2028
Sustained-Release Opioid Formulations and Methods of Use	12/418,806		NP	04/06/2029
Pharmaceutical Compositions ("Optimization")	12/710,016		NP	02/22/2030
Sequestering Subunit and Related Compositions and Methods	12/766,472		NP	04/23/2030
Sequestering Subunit and Related Compositions and Methods	12/766,488		NP	04/23/2030
Sequestering Subunit and Related Compositions and Methods	12/766,509		NP	04/23/2030
Pharmaceutical Compositions	7,682,633		NP	03/06/2029

<sup>1</sup> Within this chart, the following abbreviations are used with reference to the Type of Patent/ Application:

NP = Non-Provisional  
PSP = Provisional  
DIV = Divisional  
CIP = Continuation-in-Part

CNT = Continuation  
REI = Reissue  
DP = Design Patent

("Optimization")				
Pharmaceutical Compositions ("Optimization")	7,682,634		NP	03/06/2029

### PATENT LICENSES

<b>Name of Agreement</b>	<b>Parties Licensor/Licensee</b>	<b>Date of Agreement</b>	<b>Subject Matter</b>
Exclusive license and Distribution Agreement	IBSA (Institut Biochimique SA)/ Alpharma Pharmaceuticals LLC	August 16, 2007	Flector Patch
Exclusive License and Distribution Agreement	IBSA (Institut Biochimique SA)/ Alpharma Pharmaceuticals LLC	August 16, 2007	Tirosint